Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Both GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients.

The purpose of this study is to compare efficacy and safety of add-on treatment of sarcosine, a GlyT-1 inhibitor, and D-serine, an NMDA-glycine site agonist, in chronically stable schizophrenia patients who have been stabilized with antipsychotics.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Medical University Hospital
• Collaborators: National Health Research Institutes, Taiwan; National Science Council, Taiwan

Criteria

Inclusion Criteria:

• Fulfill the criteria of schizophrenia according to the Diagnostic and Statistic Manual, fourth edition (DSM-IV).

• Agree to participate in the study and provide informed consent.

Exclusion Criteria:

• Meet DSM-IV criteria of major mood disorder, current substance dependence or mental retardation

• History of epilepsy, head trauma or CNS diseases

• Major, untreated medical diseases

• Pregnancy or lactation